Sign in
CompletedNo phase

(FODMAP) Diet on Improving Symptoms of Patients With Irritable Bowel Syndrome

Key facts

Who runs it
Zagazig University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
183 people enrolled
Started
1 Jun 2024
Ended
30 Oct 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Low Fermentable, Oligo-, Di-, Monosaccharides and Polyols (FODMAP) Diet
Record updated
23 December 2025

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • newly diagnosed with IBS based on Rome IV criteria and subtypes of IBS included constipation-predominant, diarrhea predominant, mixed, and unspecified,
  • aged 18 to 60 years old of both genders,
  • after taking their consent to participate

Who cannot take part

  • Patients who previously diagnosed with GI comorbidities (such as inflammatory bowel disease, celiac disease, lactose malabsorption, significant diverticular disease, or a history of bowel resection)
  • drug abuse
  • Clinically significant systemic disease
  • serious psychiatric diseases
  • eating disorders
  • pregnant or lactating
  • Presence of blood or pus in stool analysis
  • Individuals with IBS-alarming symptoms as (did not have a normal colonoscopy)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction, characterized by chronic abdominal pain and altered bowel habits. A low-FODMAP diet (LFD), which restricts specific types of fermentable carbohydrates, significantly reduces IBS symptoms and improves quality of life (QoL). Objectives: To evaluate the short- and long-term effects of LFD on improving symptom severity and the quality of life of IBS patients attending the family medicine outpatient clinic, and to assess LFD acceptability and adherence of IBS patients. Methods: Randomized control trial conducted on (123 patients) with IBS attending outpatient clinic of family medicine at Tenth of Ramadan University Hospital from 1st of June 2024 to the end of June 2025. An intervention group (No=93) received patient-centered education about LFD, and a control group (No.=90). Participants in both groups underwent an assessment of their BMI, Irritable Bowel Syndrome- Severity Scoring System (IBS-SSS), and irritable bowel syndrome-Quality of Life Measure (IBS-QOL) preintervention during the first visit and reassessed post-intervention after one, three, and six months. Additionally, Patients in the intervention group were assessed for the FODMAP Adherence Report Scale (FARS), LFD acceptability questionnaire, and Food-related QOL questionnaire at one, three-, and six-month post-intervention phases.

The 2 groups in the trial

  • Intervention groupTreatment being tested

    follow low fermentable- oligo-Di- monosaccharides and polyols(FODMPD) diet as intervention program

    Treatment: Low Fermentable, Oligo-, Di-, Monosaccharides and Polyols (FODMAP) Diet

  • Control groupNo study treatment, for comparison

    control group were patients with irritable bowel syndrome don't follow any intervention program

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Low Fermentable, Oligo-, di-, Monosaccharides and Polyols (FODMAP) Diet on Improving Symptoms of Patients With Irritable Bowel Syndrome (Randomized Control Trial)
Record updated
23 December 2025